Mitochondrial Open Reading Frame of the 12S rRNA Type-c
MOTS-c (also written MOTS c or MOTSc) isn't synthetic. Your mitochondria actually make it. Levels drop as you age, and topping them back up seems to restore metabolic function that time degraded. Animal data shows improved exercise capacity, better glucose handling, and protection against age-related metabolic decline. People who run it describe a sustained, clean energy increase. Not a stimulant spike. More like your body remembering what 25 felt like. The human trial is still recruiting, so we're working from animal data and community reports for now.
Dose: 5-10mg per injection | Frequency: 2-3x per week | Cycle: 8-12 weeks on, 4 weeks off | Route: SubQ
Reconstitution: 2mL bacteriostatic water per 10mg vial. Free reconstitution calculator.
This is one of the pricier compounds because the doses are higher. Some protocols use 5mg 3x/week for a moderate approach. Take on training days if possible. The metabolic effects may synergize with exercise.
| Condition | Dose | Duration | Notes |
|---|---|---|---|
| Metabolic health and insulin sensitivity | 5mg 3x/week | 8-12 weeks | The most researched use case. MOTS-c flips the same metabolic switch that exercise does (called AMPK, basically the 'you just went for a run' signal), the same pathway exercise uses to improve glucose handling. Best tracked with fasting insulin and HbA1c labs before and after. |
| Exercise performance and endurance | 5-10mg 2-3x/week | 8-12 weeks | Pin on training days. The exercise mimetic effect means your mitochondria produce more ATP (the energy currency your cells run on, basically cellular cash). People notice better cardio capacity and faster recovery between sets. Not a pre-workout. More like upgrading your engine. |
| Body composition and fat loss | 5mg 3x/week | 12 weeks | Fat loss with MOTS-c is downstream of metabolic improvement, not appetite suppression. It's slower than GLP-1s but works through a completely different mechanism. Expect gradual recomposition, not dramatic scale drops. |
| Age-related metabolic decline | 5mg 2-3x/week | 8-12 weeks, repeat cycles | MOTS-c levels naturally decline with age. Supplementing restores what your mitochondria used to produce on their own. The longevity angle. Pair with NAD+ precursors for a full mitochondrial stack. |
MOTS-c is a 16-amino-acid peptide encoded in your mitochondrial DNA. Your body makes it naturally, but production drops as you age. It works as a messenger that tells your cells how to handle energy and blood sugar. In animal studies, supplementing MOTS-c improved insulin sensitivity, exercise capacity, and protection against age-related metabolic decline. It's sometimes called an exercise mimetic, which is science for 'some of the perks of cardio without the cardio.' You still have to work out. Sorry. It activates AMPK, the same metabolic pathway that physical exercise uses.
5mg injected subcutaneously 2-3 times per week is the most common protocol. Some people run 10mg per injection for a more aggressive approach. There's also an emerging low-dose daily protocol (0.5-1mg daily) that some users prefer for steadier levels. No human dosing trial has published results yet. These numbers come from animal study extrapolations and community consensus. Start at 5mg 3x/week and adjust based on how you respond.
The side effect profile is mild. Injection-site redness (15% of users), transient fatigue in the first 1-2 weeks (12%), mild headaches (8%), and slight resting heart rate increases (5%). The fatigue is counterintuitive since MOTS-c is supposed to boost energy. Your mitochondria are adjusting. It flips after week 2 for most people. If the heart rate change persists beyond week 3, lower the dose. Nothing serious has come up in what people are tracking so far.
Yes, but not like GLP-1s. MOTS-c doesn't suppress appetite. It improves metabolic function at the mitochondrial level, so your body burns fuel more efficiently. The result is gradual body recomposition: fat loss with lean mass preservation. Don't expect the dramatic 15% bodyweight drops you see with semaglutide or tirzepatide. MOTS-c works through a completely different mechanism. Think of it as fixing your engine, not restricting fuel.
In the research sense, yes. MOTS-c activates that exercise switch (AMPK), the same metabolic master switch that exercise triggers. In mice, mice could exercise harder even without training. But calling it exercise in a vial oversells it. It copies some of what exercise does to your metabolism, not all of them. You still need to train. MOTS-c makes your training more effective by improving the metabolic infrastructure your muscles rely on.
Add 2mL of bacteriostatic water to a 10mg vial. That gives you 5mg per mL. For a 5mg dose, draw 100 units (1mL) on a standard insulin syringe. For 10mg, you need the whole vial in one shot. Aim the water stream at the glass wall, not directly onto the powder. Swirl gently. Never shake. Store reconstituted vials in the fridge and use within 3-4 weeks.
The first 1-2 weeks can feel worse before they feel better. Fatigue and mild headaches while your mitochondria adjust. The energy shift usually hits around week 2-4. Exercise performance improvements are noticeable by week 4. Full metabolic benefits (insulin sensitivity, body composition) take 8-12 weeks. If you're tracking labs, run fasting insulin and HbA1c before you start and at the 8-week mark.
Both improve insulin sensitivity through AMPK activation. Metformin is FDA-approved, dirt cheap, and has decades of human data. MOTS-c has zero published human trials but works through a more targeted mechanism (it's something your own cells already make. Your mitochondria have been producing this since birth. Just less of it every year since you turned 25, because aging is rude). Some longevity protocols stack both. The key difference: metformin can blunt exercise adaptations. MOTS-c appears to enhance them. If you're metabolically healthy and active, that distinction matters.
Often run with: BPC-157, Ipamorelin.
Emerging evidence. MOTS-c is encoded in mitochondrial DNA and naturally declines with age. Preclinical data shows it improves insulin sensitivity, exercise capacity, and metabolic function. A human trial (MOTS-MET) has been recruiting but no results published yet. Longevity-focused people are very interested, but the human data is still catching up.
Approval status: Not approved
These statements have not been evaluated by the FDA. This content is for educational purposes only. Consult a healthcare professional before starting any protocol. vialprep sells injection supplies, not compounds.